Genetic Technologies Limited (GNTLF) 6-K 26 Feb 24 Current report (foreign) Financial data

Cover

Cover	6 Months Ended
	Dec. 31, 2023
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--06-30
Entity File Number	0-51504
Entity Registrant Name	GENETIC TECHNOLOGIES LIMITED
Entity Central Index Key	0001166272
Entity Address, Address Line One	60-66 Hanover Street
Entity Address, City or Town	Fitzroy
Entity Address, Country	AU
Entity Address, Postal Zip Code	3065

Condensed Consolidated Statemen

Condensed Consolidated Statement of Profit or Loss and Comprehensive Income	6 Months Ended
	Dec. 31, 2023 AUD ($) $ / shares	Dec. 31, 2022 AUD ($) $ / shares
Profit or loss [abstract]
Revenue	$ 3,958,682	$ 4,153,947
Finance income	89,866	79,747
Other income	914,346	823,922
Changes in inventories	(70,810)	(6,527)
Raw materials	(1,685,622)	(2,141,158)
Commissions	(99,482)	(113,415)
Employee benefits expenses	(3,803,295)	(3,109,064)
Advertising and promotional expenses	(1,154,397)	(1,537,769)
Professional fees	(737,036)	(790,612)
Research and development expenses	(389,758)	(558,306)
Depreciation and amortisation	(280,665)	(330,187)
Impairment expenses	(1,332,917)	(280,725)
Other expenses	(1,815,323)	(1,782,292)
Finance costs	(12,853)	(15,872)
Loss from operations before income tax	(6,419,264)	(5,608,311)
Income tax credit		148,013
Loss for the period	(6,419,264)	(5,460,298)
Other comprehensive income
Exchange (losses)/gains on translation of controlled foreign operations	(14,647)	15,497
Other comprehensive income for the period; net of tax	(14,647)	15,497
Owners of Genetic Technologies Limited	$ (6,433,911)	$ (5,444,801)
Loss per share for loss attributable to the ordinary equity holders of the Company:
Basic loss per share | (per share)	$ 5.56	$ 0.06
Diluted loss per share | (per share)	$ 5.56	$ 0.06

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Financial Position - AUD ($)	Dec. 31, 2023	Jun. 30, 2023
Current assets
Cash and cash equivalents	$ 3,729,200	$ 7,851,197
Trade and other receivables	1,115,450	1,921,657
Inventories	396,703	325,893
Other current assets	474,398	399,048
Total current assets	5,715,751	10,497,795
Non-current assets
Right-of-use assets	358,366	509,553
Property, plant and equipment	70,864	89,623
Goodwill	1,784,893	3,116,893
Other intangible assets	436,244	520,472
Deferred tax asset	100,744	121,901
Total non-current assets	2,751,111	4,358,442
Total assets	8,466,862	14,856,237
Current liabilities
Trade and other payables	1,916,682	1,617,333
Deferred income	764,464	849,212
Provisions	442,460	541,930
Lease liabilities	298,181	303,570
Total current liabilities	3,421,787	3,312,045
Non-current liabilities
Provisions	48,060	30,439
Lease liabilities	84,136	229,276
Deferred tax liability	100,744	121,901
Total non-current liabilities	232,940	381,616
Total liabilities	3,654,727	3,693,661
Net assets	4,812,135	11,162,576
EQUITY
Share capital	161,342,707	161,342,707
Reserves	4,247,549	6,535,556
Accumulated losses	(160,778,121)	(156,715,687)
Total equity	$ 4,812,135	$ 11,162,576

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Equity - AUD ($)	Issued capital [member]	Other reserves [member]	Retained earnings [member]	Total
Balance at Jun. 30, 2022	$ 155,138,636	$ 11,498,651	$ (150,206,216)	$ 16,431,071
IfrsStatementLineItems [Line Items]
Loss for the period			(5,460,298)	(5,460,298)
Other comprehensive gain		15,497		15,497
Total comprehensive income for the half- year		15,497	(5,460,298)	(5,444,801)
Share based payments expense		42,401		42,401
Transactions with owners in their capacity as owners		42,401		42,401
Balance at Dec. 31, 2022	155,138,636	11,556,549	(155,666,514)	11,028,671
Balance at Jun. 30, 2023	161,342,707	6,535,556	(156,715,687)	11,162,576
IfrsStatementLineItems [Line Items]
Loss for the period			(6,419,264)	(6,419,264)
Other comprehensive gain		(14,647)		(14,647)
Total comprehensive income for the half- year		(14,647)	(6,419,264)	(6,433,911)
Share based payments expense		83,470		83,470
Expiry of employee share options and performance rights		(2,356,830)	2,356,830
Transactions with owners in their capacity as owners		(2,273,360)	2,356,830	83,470
Balance at Dec. 31, 2023	$ 161,342,707	$ 4,247,549	$ (160,778,121)	$ 4,812,135

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Cash Flows - AUD ($)	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Receipts from customers	$ 3,879,692	$ 4,455,615
Payments to suppliers and employees	(9,639,697)	(10,587,443)
R&D tax incentive and other grants received	1,748,230
Net cash outflow from operating activities	(4,011,775)	(6,131,828)
Cash flows from investing activities
Payments to acquire businesses		(486,187)
Payments for property, plant and equipment	(28,239)	(3,114)
Interest received	118,222	79,747
Net cash outflow from investing activities	89,983	(409,554)
Cash flows from financing activities
Lease payments	(172,851)	(166,484)
Interest paid	(2,231)
Net cash outflow from financing activities	(175,082)	(166,484)
Net decrease in cash and cash equivalents	(4,096,874)	(6,707,866)
Cash and cash equivalents at the beginning of the financial year	7,851,197	11,731,325
Effects of exchange rate changes on cash and cash equivalents	(25,123)	21,729
Cash and cash equivalents at end of the half-year	$ 3,729,200	$ 5,045,188

Basis of preparation of half-ye

Basis of preparation of half-year report	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Basis of preparation of half-year report	Note 1: Basis of preparation of half-year report This condensed consolidated interim financial report for the half-year reporting period ended 31 December 2023 have been prepared in accordance with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001. This interim report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2023 and any public announcements made by Genetic Technologies Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001. The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period and the adoption of the new and amended standards as set out below. The Interim Financial Statements have been approved and authorised for issue by the board of directors on 23 February 2024. The consolidated financial statements of Genetic Technologies Limited group also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). Going concern For the half-year ended 31 December 2023, the group incurred a loss before income tax of $ 6,419,264 5,608,311 4,812,135 11,162,576 3,729,200 7,851,197 2,293,964 7,185,750 The Company expects to continue to incur losses and cash outflows for the foreseeable future as it continues to invest resources in research and development activities for geneType risk assessment tests and to invest in the commercialisation activities for geneType, EasyDNA and AffinityDNA, via marketing, sales, and distribution channels. The continuing viability of the Company and its ability to continue as a going concern and meet its debts and commitments as they fall due, is dependent on the satisfactory completion of an equity raising in the near future. To this end, an EGM has been scheduled for 20 March 2024, so that shareholders may approve the issue of up to 100% of its issued capital plus an attaching option/warrant. The Company has also recently signed an engagement letter with H.C. Wainwright to be its capital raising agent in the U.S. H.C. Wainwright have assisted the Company raise capital on several occasions, with the most recent raise occurring in February 2023. The Company does not currently have binding commitments from any party to subscribe for shares and any raise will be subject to maintaining active listing on the NASDAQ exchange as well as compliance with the Group’s obligations under ASX Listing Rule 7.1. Due to the uncertainty surrounding the timing, quantum, or the ability to raise additional equity, there is a material uncertainty that may cast significant doubt on the Group’s ability to continue as a going concern and therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business. However, the Directors believe that the Company will be successful in its equity raising endeavours, and has a strong track record in this regard, and accordingly, have prepared the financial report on a going concern basis. As such no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should the Group not be able to continue as a going concern.

Segment information

Segment information	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Segment information	Note 2: Segment information a. Description of segments and principal activities The Company has identified three reportable segments which is consistent with the internal reporting provided to the chief operating decision maker, the Chief Executive Officer. The three reportable segments are: ● EasyDNA: relates to EasyDNA branded test sales and expenses. ● AffinityDNA: relates to AffinityDNA branded test sales and expenses. ● geneType / Corporate: relates to geneType branded test sales and expense, including corporate charges. Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2023 Note 2: Segment information (continued) b. Business unit segments The segment information for the reportable segments is as follows: Summary of reportable segments EasyDNA AffinityDNA geneType/ Corporate Total 31 December 2023 $ $ $ $ Segment revenue & other income Revenue from contracts with customers 3,201,017 700,876 56,789 3,958,682 Other income - - 914,346 914,346 Finance income - - 89,866 89,866 Total segment revenue & other income 3,201,017 700,876 1,061,001 4,962,894 Segment expenses Depreciation and amortisation (87,216 ) (24,549 ) (168,900 ) (280,665 ) Finance costs (532 ) (995 ) (11,326 ) (12,853 ) Raw materials and change in inventories (1,455,722 ) (299,142 ) (1,568 ) (1,756,432 ) Commissions (72,698 ) (26,784 ) - (99,482 ) Employee benefits expenses (628,882 ) (127,298 ) (3,047,115 ) (3,803,295 ) Advertising and promotional expenses (516,607 ) (48,338 ) (589,452 ) (1,154,397 ) Professional fees (76,880 ) (46,101 ) (614,055 ) (737,036 ) Research and development expenses - - (389,758 ) (389,758 ) Impairment expenses (1,332,000 ) - (917 ) (1,332,917 ) Other expenses (326,365 ) (81,871 ) (1,407,087 ) (1,815,323 ) Total segment expenses (4,496,902 ) (655,078 ) (6,230,178 ) (11,382,158 ) Income tax credit - - - - Profit/(Loss) for the period (1,295,885 ) 45,798 (5,169,177 ) (6,419,264 ) Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2023 Note 2: Segment information (continued) EasyDNA AffinityDNA geneType/ Corporate Total 31 December 2022 $ $ $ $ Segment revenue & other income Revenue from contracts with customers 3,813,482 330,777 9,688 4,153,947 Other income - - 823,922 823,922 Finance income - - 79,747 79,747 Total segment revenue & other income 3,813,482 330,777 913,357 5,057,616 Segment expenses Depreciation and amortisation (15,211 ) (10,521 ) (304,455 ) (330,187 ) Finance costs (1,317 ) (1,432 ) (13,123 ) (15,872 ) Raw materials and change in inventories (1,965,338 ) (155,686 ) (26,661 ) (2,147,685 ) Commissions (97,918 ) (15,497 ) - (113,415 ) Employee benefits expenses (777,593 ) (64,277 ) (2,267,194 ) (3,109,064 ) Advertising and promotional expenses (946,757 ) (13,572 ) (577,440 ) (1,537,769 ) Professional fees (1,710 ) - (788,902 ) (790,612 ) Research and development expenses - - (558,306 ) (558,306 ) Impairment reversal/(expenses) - - (280,725 ) (280,725 ) Other expenses (462,753 ) (56,973 ) (1,262,566 ) (1,782,292 ) Total segment expenses (4,268,597 ) (317,958 ) (6,079,372 ) (10,665,927 ) Income tax expenses - - 148,013 148,013 Loss for the period (455,115 ) 12,819 (5,018,002 ) (5,460,298 )

Revenue

Revenue	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Revenue	Note 3: Revenue Schedule of revenue 31 December 2023 31 December 2022 $ $ Sales of EasyDNA branded tests - point in time 3,201,017 3,813,482 Sales of AffinityDNA branded tests - point in time 700,876 330,777 Sales of geneType branded tests - point in time 56,789 9,688 Revenue from contract with customers 3,958,682 4,153,947 Revenue recognition The Company operates facilities that provide genetic testing services and recognises revenue as follows: ● Revenues from the provision of genetic and clinical risk testing for cancer and other serious diseases under the geneType brand are recognised at a point time when the Company has provided the customer with their test results, the single performance obligation. ● Revenue from provision of genetic test direct to consumer under the EasyDNA and AffinityDNA brand is recognised at a point in time when the Company has provided the customer with their test results, the single performance obligation. Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2023

Equity

Equity	6 Months Ended
	Dec. 31, 2023
Equity	Note 4: Equity a. Quoted securities - movement in ordinary shares on issue Schedule of movement in ordinary shares on issue Number of Ordinary Shares Total $ Balance at 1 July 2022 9,233,965,143 155,138,636 Shares issued during the financial year 2,307,693,000 7,172,399 Performance rights exercised - 82,688 Transaction costs arising from shares issued - (916,060 ) Valuation of warrants - (134,956 ) Share consolidation* (11,426,240,897 ) - At 30 June 2023 11,541,658,143 161,342,707 Number of Ordinary Shares Total $ Balance at 1 July 2023 11,541,658,143 161,342,707 Share consolidation* (11,426,240,897 ) - At 31 December 2023 115,417,246 161,342,707 * On 18 December 2023 GTG undertook a share consolidation of its equity securities on the basis of 1 security for every 100 securities held. Shareholders approved the equity consolidation at the 2023 Annual General Meeting (AGM). b. Unquoted securities - movement in performance rights, options and warrants No NIL 8,400,000 479,500,000 1,500,000 NIL Summary of employee share and options plan Performance Rights Options and warrants Total Total Number Number Number $ Balance at 1 July 2023 225,000,000 277,166,778 502,166,778 5,688,148 Share based payments expense - - - 83,470 Forfeited performance rights (125,000,000 ) - (125,000,000 ) (2,356,830 ) Lapsed options - (8,400,000 ) (8,400,000 ) - Balance before share consolidation 100,000,000 268,766,778 368,766,778 3,414,788 Share consolidation* (99,000,000 ) (266,079,110 ) (365,079,110 ) - Warrants issued# - 1,942,500 1,942,500 - At 31 December 2023 1,000,000 4,630,168 5,630,168 3,414,788 * On 18 December 2023 GTG undertook a share consolidation of its equity securities on the basis of 1 security for every 100 securities held. Shareholders approved the equity consolidation at the 2023 AGM. # Made up of the issue of 1,500,000 additional 442,500 Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2023 Note 4: Equity b. Unquoted securities - movement in performance rights, options and warrants (continued) Performance Rights Options and Warrants Total Total Number Number Number $ Balance at 1 July 2022 265,000,000 756,666,778 1,021,666,778 10,751,832 Share based payments expense - - - 333,829 Forfeited performance rights (40,000,000 ) - (40,000,000 ) (291,428 ) Lapsed options - (479,500,000 ) (479,500,000 ) - At 31 December 2022 225,000,000 277,166,778 502,166,778 10,794,233 c. Other reserves Summary of other reserves Share based payments Foreign currency translation Total $ $ $ Balance at 1 July 2023 5,688,148 847,408 6,535,556 Currency translation differences - (14,647 ) (14,647 ) Other comprehensive income for the period - (14,647 ) (14,647 ) Share based payments expense 83,470 - 83,470 Expired performance rights and options (2,356,830 ) - (2,356,830 ) At 31 December 2023 3,414,788 832,761 4,247,549 Share based payments Foreign currency translation Total $ $ $ Balance at 1 July 2022 10,751,832 746,819 11,498,651 Currency translation differences - 15,497 15,497 Other comprehensive income for the period - 15,497 15,497 Share based payments expense 333,829 - 333,829 Forfeited performance rights (291,428 ) - (291,428 ) At 31 December 2022 10,794,233 762,316 11,556,549 Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2023

Loss per share

Loss per share	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Loss per share	Note 5: Loss per share Summary of earnings per share and weighted average number of shares a. Reconciliation of earnings used in calculating earnings per share 31 December 2023 31 December 2022 $ $ Basic earnings per share: Loss attributable to the ordinary equity holders of the Company used in calculating basic/diluted earnings per share: From continuing operations (6,419,264 ) (5,460,298 ) b. Weighted average number of shares used as denominator 31 December 2023 31 December 2022 Number Number Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share * 115,417,246 9,233,965,143 Basic/diluted loss per share (cents per share) 5.56 0.06 * The calculation of diluted loss per share - potential ordinary shares are considered anti-dilutive, therefore diluted loss per share is equivalent to basic loss per share.

Goodwill

Goodwill	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Goodwill	Note 6: Goodwill The following table shows the movements in goodwill: Summary of changes in goodwill 31 December 2023 30 June 2023 $ $ Gross carrying amount Balance at beginning of period 4,961,893 4,506,653 Acquired through business combination - 455,240 Balance at end of period 4,961,893 4,961,893 Accumulated impairment Balance at beginning of period (1,845,000 ) - Impairment loss recognised (1,332,000 ) (1,845,000 ) Balance at end of period (3,177,000 ) (1,845,000 ) Carrying amount at the end of the period 1,784,893 3,116,893 Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2023

Related party transactions

Related party transactions	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Related party transactions	Note 7: Related party transactions a. Parent entities i. Ultimate parent Genetic Technologies Limited is the ultimate Australian parent Company. As at the date of this report, no shareholder controls more than 50% of the issued capital of the Company. b. Transactions with other related parties During the half-year ended 31 December 2023, the only transactions between entities within the group and other related parties are as listed below. Except where noted, all amounts were charged on similar to market terms and at commercial rates. i. Mr Peter Rubinstein (Non-Executive Director and Chairman) During the financial year ended June 30, 2020, the board of directors approved the payment of consulting services to Non-Executive Director and current Chairman, Mr Peter Rubinstein, for his advice relating to capital raises, compliance, NASDAQ hearings and investor relations. The services were procured through Mr Peter Rubinstein’s associate entity ValueAdmin.com Pty Ltd. During the current reporting period these consulting fees amounted to $ 33,000 33,000 ii. Dr George Muchnicki (Executive Director) During the reporting period the board of directors approved the payment of consulting services to Executive Director, Dr George Muchnicki, for his advice relating to precision genomics. The services were procured through Dr Muchnicki’s asso- ciate entity, JGM Investment Group. During the current reporting period these consulting fees amounted to $ 11,000 NIL

Events occurring after the repo

Events occurring after the reporting period	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Events occurring after the reporting period	Note 8: Events occurring after the reporting period On 20 February 2024, shareholders were informed that an Extraordinary General Meeting (EGM) was to be held on 20 March 2024. The item of business for this meeting is to provide approval for the issuance of up to an additional 100% On 15 February 2024, GTG announced the resignation of independent Non-executive Director, Mr Nick Burrows, and its intention to appoint two new directors with significant commercial experience. No other matter or circumstance has arisen since 31 December 2023 that has significantly affected or may significantly affect: (a) the Group’s operations in future years; or (b) the results of those operations in future years; or (c) the Group’s state of affairs in future years.

Segment information (Tables)

Segment information (Tables)	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Summary of reportable segments	The segment information for the reportable segments is as follows: Summary of reportable segments EasyDNA AffinityDNA geneType/ Corporate Total 31 December 2023 $ $ $ $ Segment revenue & other income Revenue from contracts with customers 3,201,017 700,876 56,789 3,958,682 Other income - - 914,346 914,346 Finance income - - 89,866 89,866 Total segment revenue & other income 3,201,017 700,876 1,061,001 4,962,894 Segment expenses Depreciation and amortisation (87,216 ) (24,549 ) (168,900 ) (280,665 ) Finance costs (532 ) (995 ) (11,326 ) (12,853 ) Raw materials and change in inventories (1,455,722 ) (299,142 ) (1,568 ) (1,756,432 ) Commissions (72,698 ) (26,784 ) - (99,482 ) Employee benefits expenses (628,882 ) (127,298 ) (3,047,115 ) (3,803,295 ) Advertising and promotional expenses (516,607 ) (48,338 ) (589,452 ) (1,154,397 ) Professional fees (76,880 ) (46,101 ) (614,055 ) (737,036 ) Research and development expenses - - (389,758 ) (389,758 ) Impairment expenses (1,332,000 ) - (917 ) (1,332,917 ) Other expenses (326,365 ) (81,871 ) (1,407,087 ) (1,815,323 ) Total segment expenses (4,496,902 ) (655,078 ) (6,230,178 ) (11,382,158 ) Income tax credit - - - - Profit/(Loss) for the period (1,295,885 ) 45,798 (5,169,177 ) (6,419,264 ) Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2023 Note 2: Segment information (continued) EasyDNA AffinityDNA geneType/ Corporate Total 31 December 2022 $ $ $ $ Segment revenue & other income Revenue from contracts with customers 3,813,482 330,777 9,688 4,153,947 Other income - - 823,922 823,922 Finance income - - 79,747 79,747 Total segment revenue & other income 3,813,482 330,777 913,357 5,057,616 Segment expenses Depreciation and amortisation (15,211 ) (10,521 ) (304,455 ) (330,187 ) Finance costs (1,317 ) (1,432 ) (13,123 ) (15,872 ) Raw materials and change in inventories (1,965,338 ) (155,686 ) (26,661 ) (2,147,685 ) Commissions (97,918 ) (15,497 ) - (113,415 ) Employee benefits expenses (777,593 ) (64,277 ) (2,267,194 ) (3,109,064 ) Advertising and promotional expenses (946,757 ) (13,572 ) (577,440 ) (1,537,769 ) Professional fees (1,710 ) - (788,902 ) (790,612 ) Research and development expenses - - (558,306 ) (558,306 ) Impairment reversal/(expenses) - - (280,725 ) (280,725 ) Other expenses (462,753 ) (56,973 ) (1,262,566 ) (1,782,292 ) Total segment expenses (4,268,597 ) (317,958 ) (6,079,372 ) (10,665,927 ) Income tax expenses - - 148,013 148,013 Loss for the period (455,115 ) 12,819 (5,018,002 ) (5,460,298 )

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Schedule of revenue	Schedule of revenue 31 December 2023 31 December 2022 $ $ Sales of EasyDNA branded tests - point in time 3,201,017 3,813,482 Sales of AffinityDNA branded tests - point in time 700,876 330,777 Sales of geneType branded tests - point in time 56,789 9,688 Revenue from contract with customers 3,958,682 4,153,947

Equity (Tables)

Equity (Tables)	6 Months Ended
	Dec. 31, 2023
Schedule of movement in ordinary shares on issue	Schedule of movement in ordinary shares on issue Number of Ordinary Shares Total $ Balance at 1 July 2022 9,233,965,143 155,138,636 Shares issued during the financial year 2,307,693,000 7,172,399 Performance rights exercised - 82,688 Transaction costs arising from shares issued - (916,060 ) Valuation of warrants - (134,956 ) Share consolidation* (11,426,240,897 ) - At 30 June 2023 11,541,658,143 161,342,707 Number of Ordinary Shares Total $ Balance at 1 July 2023 11,541,658,143 161,342,707 Share consolidation* (11,426,240,897 ) - At 31 December 2023 115,417,246 161,342,707 * On 18 December 2023 GTG undertook a share consolidation of its equity securities on the basis of 1 security for every 100 securities held. Shareholders approved the equity consolidation at the 2023 Annual General Meeting (AGM).
Summary of employee share and options plan	Summary of employee share and options plan Performance Rights Options and warrants Total Total Number Number Number $ Balance at 1 July 2023 225,000,000 277,166,778 502,166,778 5,688,148 Share based payments expense - - - 83,470 Forfeited performance rights (125,000,000 ) - (125,000,000 ) (2,356,830 ) Lapsed options - (8,400,000 ) (8,400,000 ) - Balance before share consolidation 100,000,000 268,766,778 368,766,778 3,414,788 Share consolidation* (99,000,000 ) (266,079,110 ) (365,079,110 ) - Warrants issued# - 1,942,500 1,942,500 - At 31 December 2023 1,000,000 4,630,168 5,630,168 3,414,788 * On 18 December 2023 GTG undertook a share consolidation of its equity securities on the basis of 1 security for every 100 securities held. Shareholders approved the equity consolidation at the 2023 AGM. # Made up of the issue of 1,500,000 additional 442,500 Genetic Technologies Limited Notes to the condensed consolidated financial statements 31 December 2023 Note 4: Equity b. Unquoted securities - movement in performance rights, options and warrants (continued) Performance Rights Options and Warrants Total Total Number Number Number $ Balance at 1 July 2022 265,000,000 756,666,778 1,021,666,778 10,751,832 Share based payments expense - - - 333,829 Forfeited performance rights (40,000,000 ) - (40,000,000 ) (291,428 ) Lapsed options - (479,500,000 ) (479,500,000 ) - At 31 December 2022 225,000,000 277,166,778 502,166,778 10,794,233
Summary of other reserves	Summary of other reserves Share based payments Foreign currency translation Total $ $ $ Balance at 1 July 2023 5,688,148 847,408 6,535,556 Currency translation differences - (14,647 ) (14,647 ) Other comprehensive income for the period - (14,647 ) (14,647 ) Share based payments expense 83,470 - 83,470 Expired performance rights and options (2,356,830 ) - (2,356,830 ) At 31 December 2023 3,414,788 832,761 4,247,549 Share based payments Foreign currency translation Total $ $ $ Balance at 1 July 2022 10,751,832 746,819 11,498,651 Currency translation differences - 15,497 15,497 Other comprehensive income for the period - 15,497 15,497 Share based payments expense 333,829 - 333,829 Forfeited performance rights (291,428 ) - (291,428 ) At 31 December 2022 10,794,233 762,316 11,556,549

Loss per share (Tables)

Loss per share (Tables)	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Summary of earnings per share and weighted average number of shares	Summary of earnings per share and weighted average number of shares a. Reconciliation of earnings used in calculating earnings per share 31 December 2023 31 December 2022 $ $ Basic earnings per share: Loss attributable to the ordinary equity holders of the Company used in calculating basic/diluted earnings per share: From continuing operations (6,419,264 ) (5,460,298 ) b. Weighted average number of shares used as denominator 31 December 2023 31 December 2022 Number Number Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share * 115,417,246 9,233,965,143 Basic/diluted loss per share (cents per share) 5.56 0.06 * The calculation of diluted loss per share - potential ordinary shares are considered anti-dilutive, therefore diluted loss per share is equivalent to basic loss per share.

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Summary of changes in goodwill	The following table shows the movements in goodwill: Summary of changes in goodwill 31 December 2023 30 June 2023 $ $ Gross carrying amount Balance at beginning of period 4,961,893 4,506,653 Acquired through business combination - 455,240 Balance at end of period 4,961,893 4,961,893 Accumulated impairment Balance at beginning of period (1,845,000 ) - Impairment loss recognised (1,332,000 ) (1,845,000 ) Balance at end of period (3,177,000 ) (1,845,000 ) Carrying amount at the end of the period 1,784,893 3,116,893

Summary of reportable segments

Summary of reportable segments (Details) - AUD ($)	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Revenue from contracts with customers	$ 3,958,682	$ 4,153,947
Other income	914,346	823,922
Finance income	89,866	79,747
Total segment revenue & other income	4,962,894	5,057,616
Depreciation and amortisation	(280,665)	(330,187)
Finance costs	(12,853)	(15,872)
Raw materials and change in inventories	(1,756,432)	(2,147,685)
Commissions	(99,482)	(113,415)
Employee benefits expenses	(3,803,295)	(3,109,064)
Advertising and promotional expenses	(1,154,397)	(1,537,769)
Professional fees	(737,036)	(790,612)
Research and development expenses	(389,758)	(558,306)
Impairment reversal/(expenses)	(1,332,917)	(280,725)
Other expenses	(1,815,323)	(1,782,292)
Total segment expenses	(11,382,158)	(10,665,927)
Income tax expenses		148,013
Loss for the period	(6,419,264)	(5,460,298)
Easy DNA [member]
IfrsStatementLineItems [Line Items]
Revenue from contracts with customers	3,201,017	3,813,482
Other income
Finance income
Total segment revenue & other income	3,201,017	3,813,482
Depreciation and amortisation	(87,216)	(15,211)
Finance costs	(532)	(1,317)
Raw materials and change in inventories	(1,455,722)	(1,965,338)
Commissions	(72,698)	(97,918)
Employee benefits expenses	(628,882)	(777,593)
Advertising and promotional expenses	(516,607)	(946,757)
Professional fees	(76,880)	(1,710)
Research and development expenses
Impairment reversal/(expenses)	(1,332,000)
Other expenses	(326,365)	(462,753)
Total segment expenses	(4,496,902)	(4,268,597)
Income tax expenses
Loss for the period	(1,295,885)	(455,115)
Affinity DNA [member]
IfrsStatementLineItems [Line Items]
Revenue from contracts with customers	700,876	330,777
Other income
Finance income
Total segment revenue & other income	700,876	330,777
Depreciation and amortisation	(24,549)	(10,521)
Finance costs	(995)	(1,432)
Raw materials and change in inventories	(299,142)	(155,686)
Commissions	(26,784)	(15,497)
Employee benefits expenses	(127,298)	(64,277)
Advertising and promotional expenses	(48,338)	(13,572)
Professional fees	(46,101)
Research and development expenses
Impairment reversal/(expenses)
Other expenses	(81,871)	(56,973)
Total segment expenses	(655,078)	(317,958)
Income tax expenses
Loss for the period	45,798	12,819
GeneType/Corporate [member]
IfrsStatementLineItems [Line Items]
Revenue from contracts with customers	56,789	9,688
Other income	914,346	823,922
Finance income	89,866	79,747
Total segment revenue & other income	1,061,001	913,357
Depreciation and amortisation	(168,900)	(304,455)
Finance costs	(11,326)	(13,123)
Raw materials and change in inventories	(1,568)	(26,661)
Commissions
Employee benefits expenses	(3,047,115)	(2,267,194)
Advertising and promotional expenses	(589,452)	(577,440)
Professional fees	(614,055)	(788,902)
Research and development expenses	(389,758)	(558,306)
Impairment reversal/(expenses)	(917)	(280,725)
Other expenses	(1,407,087)	(1,262,566)
Total segment expenses	(6,230,178)	(6,079,372)
Income tax expenses		148,013
Loss for the period	$ (5,169,177)	$ (5,018,002)

Schedule of revenue (Details)

Schedule of revenue (Details) - AUD ($)	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Revenue from contract with customers	$ 3,958,682	$ 4,153,947
EasyDNA Branded Tests [member] | Goods or services transferred at point in time [member]
IfrsStatementLineItems [Line Items]
Revenue from contract with customers	3,201,017	3,813,482
Affinity DNA Branded Tests [member] | Goods or services transferred at point in time [member]
IfrsStatementLineItems [Line Items]
Revenue from contract with customers	700,876	330,777
GeneType Branded Tests [member] | Goods or services transferred at point in time [member]
IfrsStatementLineItems [Line Items]
Revenue from contract with customers	$ 56,789	$ 9,688

Basis of preparation of half-_2

Basis of preparation of half-year report (Details Narrative) - AUD ($)	6 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2022	Jun. 30, 2023
Notes and other explanatory information [abstract]
Loss befor income tax	$ 6,419,264	$ 5,608,311	$ 5,608,311
Net assets	4,812,135			$ 11,162,576
Cash	3,729,200			7,851,197
Net current assets	$ 2,293,964			$ 7,185,750

Schedule of movement in ordinar

Schedule of movement in ordinary shares on issue (Details) - AUD ($)		6 Months Ended	12 Months Ended
		Dec. 31, 2023	Jun. 30, 2023
Number of shares at beginning		11,541,658,143	9,233,965,143
Contributed equity, at the beginning		$ 161,342,707	$ 155,138,636
Shares issued during the year (in shares)			2,307,693,000
Shares issued during the year			$ 7,172,399
Shares issued during the year (in shares)
Exercise of performance rights			$ 82,688
Transaction costs arising on share issue (in shares)
Less: transaction costs arising on share issue			$ (916,060)
Valuation of warrants to be issued (in shares)
Valuation of warrants to be issued			$ (134,956)
Share consolidation (in shares)	[1]	(11,426,240,897)
Share consolidation	[1]
Number of shares at end		115,417,246	11,541,658,143
Contributed equity, at the end		$ 161,342,707	$ 161,342,707
[1]On 18 December 2023 GTG undertook a share consolidation of its equity securities on the basis of 1 security for every 100 securities held. Shareholders approved the equity consolidation at the 2023 Annual General Meeting (AGM).

Summary of employee share and o

Summary of employee share and options plan (Details)		6 Months Ended
		Dec. 31, 2023 AUD ($) shares	Dec. 31, 2022 AUD ($) shares
IfrsStatementLineItems [Line Items]
Unquoted securities, beginning balance | $		$ 5,688,148	$ 10,751,832
Share based payments expense | $		83,470	333,829
Forfeited performance rights | $		(2,356,830)	(291,428)
Lapsed options | $
Balance before share consolidation | $		3,414,788
Share consolidation | $	[1]
Warrants issued | $	[2]
Unquoted securities, ending balance | $		$ 3,414,788	$ 10,794,233
Performance Rights [member]
IfrsStatementLineItems [Line Items]
Options and warrants, beginning balance		225,000,000	265,000,000
Share based payments expense
Forfeited performance rights		(125,000,000)	(40,000,000)
Lapsed options
Balance before share consolidation		100,000,000
Share consolidation	[1]	(99,000,000)
Warrants issued	[2]
Options and warrants, ending balance		1,000,000	225,000,000
Options and warrants [member]
IfrsStatementLineItems [Line Items]
Options and warrants, beginning balance		277,166,778	756,666,778
Share based payments expense
Forfeited performance rights
Lapsed options		(8,400,000)	(479,500,000)
Balance before share consolidation		268,766,778
Share consolidation	[1]	(266,079,110)
Warrants issued	[2]	1,942,500
Options and warrants, ending balance		4,630,168	277,166,778
Performance rights and options and warrants [member]
IfrsStatementLineItems [Line Items]
Options and warrants, beginning balance		502,166,778	1,021,666,778
Share based payments expense
Forfeited performance rights		(125,000,000)	(40,000,000)
Lapsed options		(8,400,000)	(479,500,000)
Balance before share consolidation		368,766,778
Share consolidation	[1]	(365,079,110)
Warrants issued	[2]	1,942,500
Options and warrants, ending balance		5,630,168	502,166,778
[1]On 18 December 2023 GTG undertook a share consolidation of its equity securities on the basis of 1 security for every 100 securities held. Shareholders approved the equity consolidation at the 2023 AGM.[2]Made up of the issue of 1,500,000

Summary of employee share and_2

Summary of employee share and options plan (Details) (Parenthetical) - shares	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Warrants issued to raise capital	1,500,000
Warrants issued to raise capital but not reported	442,500

Summary of other reserves (Deta

Summary of other reserves (Details) - AUD ($)	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
IfrsStatementLineItems [Line Items]
Reserves, beginning balance	$ 6,535,556	$ 11,498,651
Currency translation differences	(14,647)	15,497
Other comprehensive income for the period	(14,647)	15,497
Share based payments expense	83,470	42,401
Expired performance rights and options	(2,356,830)
Reserves, ending balance	4,247,549	11,556,549
Share based payments expense		333,829
Expired performance rights		(291,428)
Reserve of share-based payments [member]
IfrsStatementLineItems [Line Items]
Reserves, beginning balance	5,688,148	10,751,832
Currency translation differences
Other comprehensive income for the period
Share based payments expense	83,470
Expired performance rights and options	(2,356,830)
Reserves, ending balance	3,414,788	10,794,233
Share based payments expense		333,829
Expired performance rights		(291,428)
Foreign currency translation [member]
IfrsStatementLineItems [Line Items]
Reserves, beginning balance	847,408	746,819
Currency translation differences	(14,647)	15,497
Other comprehensive income for the period	(14,647)	15,497
Share based payments expense
Expired performance rights and options
Reserves, ending balance	$ 832,761	762,316
Share based payments expense
Expired performance rights

Equity (Details Narrative)

Equity (Details Narrative)	6 Months Ended
	Dec. 31, 2023 Integer shares	Dec. 31, 2022 Integer shares
IfrsStatementLineItems [Line Items]
Warrants issued to raise capital	1,500,000
Performance Rights [member]
IfrsStatementLineItems [Line Items]
Issue of performance rights | Integer	0
Options [member]
IfrsStatementLineItems [Line Items]
Lapsed options	8,400,000	479,500,000

Summary of earnings per share a

Summary of earnings per share and weighted average number of shares (Details)		6 Months Ended
		Dec. 31, 2023 $ / shares	Dec. 31, 2023 AUD ($) $ / shares shares	Dec. 31, 2022 $ / shares	Dec. 31, 2022 AUD ($) $ / shares shares
Notes and other explanatory information [abstract]
From continuing operations | $			$ (6,419,264)		$ (5,460,298)
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share	[1]		115,417,246		9,233,965,143
Weighted average number of ordinary shares used as the denominator in calculating diluted loss per share	[1]		115,417,246		9,233,965,143
Basic loss per share | (per share)		$ 5.56	$ 5.56	$ 0.06	$ 0.06
Diluted loss per share | (per share)		$ 5.56	$ 5.56	$ 0.06	$ 0.06
[1]The calculation of diluted loss per share - potential ordinary shares are considered anti-dilutive, therefore diluted loss per share is equivalent to basic loss per share.

Summary of changes in goodwill

Summary of changes in goodwill (Details) - AUD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2023	Jun. 30, 2023
IfrsStatementLineItems [Line Items]
Balance at beginning of period	$ 3,116,893
Carrying amount at the end of the period	1,784,893	$ 3,116,893
Gross carrying amount [member]
IfrsStatementLineItems [Line Items]
Balance at beginning of period	4,961,893	4,506,653
Acquired through business combination		455,240
Carrying amount at the end of the period	4,961,893	4,961,893
Accumulated impairment [member]
IfrsStatementLineItems [Line Items]
Balance at beginning of period	(1,845,000)
Carrying amount at the end of the period	(3,177,000)	(1,845,000)
Impairment loss recognised	$ (1,332,000)	$ (1,845,000)

Related party transactions (Det

Related party transactions (Details Narrative) - AUD ($)	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Mr Peter Rubinstein [member]
IfrsStatementLineItems [Line Items]
Services received, related party transactions	$ 33,000	$ 33,000
Dr George Muchnicki [member]
IfrsStatementLineItems [Line Items]
Consulting fees	$ 11,000

Events occurring after the re_2

Events occurring after the reporting period (Details Narrative)	Feb. 20, 2024
Nonadjusting Events After Reporting Period [member]
IfrsStatementLineItems [Line Items]
Issued capital percentage	100%